{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:52:42Z","timestamp":1793908362067,"version":"4.8.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["HHSN268201200036C"],"award-info":[{"award-number":["HHSN268201200036C"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["HHSN268200800007C"],"award-info":[{"award-number":["HHSN268200800007C"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N01 HC55222"],"award-info":[{"award-number":["N01 HC55222"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N01HC85079"],"award-info":[{"award-number":["N01HC85079"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N01HC85080"],"award-info":[{"award-number":["N01HC85080"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N01HC85081"],"award-info":[{"award-number":["N01HC85081"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N01HC85082"],"award-info":[{"award-number":["N01HC85082"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N01HC85083"],"award-info":[{"award-number":["N01HC85083"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["N01HC85086"],"award-info":[{"award-number":["N01HC85086"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute (NHLBI)","doi-asserted-by":"crossref","award":["HL080295"],"award-info":[{"award-number":["HL080295"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Institute on Aging (NIA)","award":["AG023629"],"award-info":[{"award-number":["AG023629"]}]}],"content-domain":{"domain":["atherosclerosis-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.atherosclerosis.2013.09.002","type":"journal-article","created":{"date-parts":[[2013,9,13]],"date-time":"2013-09-13T02:51:25Z","timestamp":1379040685000},"page":"114-119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults"],"prefix":"10.1016","volume":"231","author":[{"given":"Anna","family":"Jovanovich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim H.","family":"Ix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gottdiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"McFann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronit","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Kestenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian H.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Sarnak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Shlipak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"Mukamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siscovick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Chonchol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.atherosclerosis.2013.09.002_bib1","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1681\/ASN.2007010068","article-title":"How fibroblast growth factor 23 works","volume":"18","author":"Liu","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.atherosclerosis.2013.09.002_bib2","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2013.09.002_bib3","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","article-title":"Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the MILD to Moderate Kidney Disease (MMKD) Study","volume":"18","author":"Fliser","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.09.002_bib4","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1093\/ndt\/gfp699","article-title":"Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study","volume":"25","author":"Ix","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2013.09.002_bib5","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1681\/ASN.2010121224","article-title":"FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis","volume":"22","author":"Kendrick","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.atherosclerosis.2013.09.002_bib6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","article-title":"The associations of fibroblast growth factor 23 and uncarboxylated matrix GIa protein with mortality in coronary artery disease: the Heart and Soul Study","volume":"152","author":"Parker","year":"2010","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.09.002_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jacc.2012.03.040","article-title":"Fibroblast growth Factor-23 and death, heart failure, and cardiovascular events in community-living Individuals: CHS (Cardiovascular Health Study)","volume":"60","author":"Ix","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"19","key":"10.1016\/j.atherosclerosis.2013.09.002_bib8","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2013.09.002_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/MAJ.0b013e3181815498","article-title":"Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients","volume":"337","author":"Hsu","year":"2009","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2013.09.002_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.atherosclerosis.2009.05.013","article-title":"Serum intact FGF23 associated with left ventricular mass, hypertrophy and geometry in an elderly population","volume":"207","author":"Mirza","year":"2009","journal-title":"Atherosclerosis"},{"issue":"11","key":"10.1016\/j.atherosclerosis.2013.09.002_bib11","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J\u00a0Clin Invest"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.09.002_bib12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/1047-2797(91)90005-W","article-title":"The Cardiovascular Health Study: design and rationale","volume":"1","author":"Fried","year":"1991","journal-title":"Ann Epidemiol"},{"issue":"17","key":"10.1016\/j.atherosclerosis.2013.09.002_bib13","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2013.09.002_bib14","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0894-7317(14)80105-3","article-title":"Echocardiographic design of a multicenter investigation of free-living elderly subjects: the Cardiovascular Health Study","volume":"5","author":"Gardin","year":"1992","journal-title":"J\u00a0Am Soc Echocardiogr"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2013.09.002_bib15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0002-9149(86)90771-X","article-title":"Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings","volume":"57","author":"Devereux","year":"1986","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2013.09.002_bib16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1055\/s-0038-1634798","article-title":"Methodology of ECG interpretation in the Dalhousie program; NOVACODE ECG classification procedures for clinical trials and population health surveys","volume":"29","author":"Rautaharju","year":"1990","journal-title":"Methods Inf Med"},{"issue":"Suppl.","key":"10.1016\/j.atherosclerosis.2013.09.002_bib17","first-page":"179","article-title":"NOVACODE serial ECG classification system for clinical trials and epidemiologic studies","volume":"24","author":"Rautaharju","year":"1992","journal-title":"J\u00a0Electrocardiol"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.09.002_bib18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1054\/jelc.2000.7667","article-title":"Race- and sex-specific ECG models for left ventricular mass in older populations. Factors influencing overestimation of left ventricular hypertrophy prevalence by ECH criteria in African-Americans","volume":"33","author":"Rautaharju","year":"2000","journal-title":"J\u00a0Electrocardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2013.09.002_bib19","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/01.HYP.28.1.8","article-title":"Utility of new electrocardiographic models for left ventricular mass in older adults. The Cardiovascular Health Study Collaborative Research Group","volume":"28","author":"Rautaharju","year":"1996","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2013.09.002_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCULATIONAHA.104.504159","article-title":"C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the Cardiovascular Health Study","volume":"112","author":"Cushman","year":"2005","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.atherosclerosis.2013.09.002_bib21","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1056\/NEJMoa043161","article-title":"Cystatin C and the risk of death and cardiovascular events among elderly persons","volume":"352","author":"Shlipak","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.atherosclerosis.2013.09.002_bib22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1053\/j.ajkd.2007.11.018","article-title":"Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD","volume":"51","author":"Stevens","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"7120","key":"10.1016\/j.atherosclerosis.2013.09.002_bib23","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature05315","article-title":"Klotho converts canonical FGF receptor into a specific receptor for FGF23","volume":"444","author":"Urakawa","year":"2006","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.atherosclerosis.2013.09.002_bib24","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1172\/JCI61405","article-title":"FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality","volume":"122","author":"Shalhoub","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.atherosclerosis.2013.09.002_bib25","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1111\/j.1523-1755.2004.66013.x","article-title":"Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure","volume":"66","author":"Neves","year":"2004","journal-title":"Kidney Int"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2013.09.002_bib26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1365-2796.2005.01544.x","article-title":"Left ventricular function and calcium phosphate plasma levels in uraemic patients","volume":"258","author":"Galetta","year":"2005","journal-title":"J\u00a0Intern Med"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2013.09.002_bib27","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1681\/ASN.2010121251","article-title":"Cross talk between the renin-angiotensin-aldosterone system and vitamin D-FGF-23-klotho in chronic kidney disease","volume":"22","author":"de Borst","year":"2011","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.atherosclerosis.2013.09.002_bib28","doi-asserted-by":"crossref","first-page":"e444161","DOI":"10.1371\/journal.pone.0044161","article-title":"A\u00a0comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model","volume":"7","author":"Dai","year":"2012","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2013.09.002_bib29","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1172\/JCI16980","article-title":"Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice","volume":"116","author":"Gurley","year":"2006","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.atherosclerosis.2013.09.002_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.2012090894","article-title":"Fractional excretion of phosphorus modifies the association between fibroblast growth factor-23 and outcomes","volume":"24","author":"Dominguez","year":"2013","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.atherosclerosis.2013.09.002_bib31","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.jacc.2003.11.040","article-title":"Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry","volume":"43","author":"Klapholz","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.atherosclerosis.2013.09.002_bib32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jacc.2006.08.050","article-title":"Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: the role of atrial remodeling\/dysfunction","volume":"49","author":"Melenovsky","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.atherosclerosis.2013.09.002_bib33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Hearth Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013005182?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013005182?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T02:06:03Z","timestamp":1563933963000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915013005182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0021915013005182"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.09.002","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}